Making the Most of Your NIH Phase II Small Business Award

Chris Sasiela, PhD, RAC: Director, SEED Innovator Support Services Stephanie Fertig, MBA: Director, NIH Small Business Program

NIH Phase II awardees

Ana Moreno, PhD: Founder and CEO Navega Therapeutics

Mo Chen, MBA, PhD: Founder and CEO WNT Scientific

OFFICE OF EXTRAMURAL RESEARCH | OFFICE OF THE DIRECTOR | NATIONAL INSTITUTES OF HEALTH

This presentation may include presenter's notes.




Webinar Housekeeping

- Note: This webinar is being recorded. The recording and materials will be made available to participants 7 business days after the session.
- Please submit all questions in the Q&A box located in your control panel.



Small Business Program Website



http://seed.nih.gov



NIH Mission











To seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

The Small Business Program helps NIH accelerate discoveries from bench to bedside



Benefits of NIH Funding


The largest sources of early-stage capital for life sciences in the US

Proof of Research and Basic Research Scale-up and Sales and Development Manufacturing Distribution Discovery Concept **Research Grants** "Free Money" - Non-dilutive capital and not a loan Awardees can leverage funding to attract investors and partners Friends, Family, and Founders **Angel Investors Venture Capital** Company Formed **Strategic Partners**



Phased Programs

(SBIR only)



Participate

*NIH, CDC, ARPA-H have a waiver from the Small Business Administration to exceed these budgets for selected <u>topics</u>

Phase II: \$2,045,816/1-3 years*



Phase IIB vs. CRP

Competing Renewal (Phase IIB)

- After Phase II award only
- Phase II out-sourcing guidelines
- Accepted Through Omnibus (<u>if</u> allowed by IC) or specific funding opportunities
- Encourages matching funding

Commercialization Readiness Pilot (CRP)

- Concurrent with or after Phase II award
- Significant out-sourcing is allowed
- Through specific Funding Opportunities ONLY

Trans-NIH Funding Opportunities:

PAR-23-219: Clinical Trial Not Allowed

PAR-23-220: Clinical Trial Required

Only Some NIH Institutes/Centers Participate
Contact Program Staff BEFORE submission!



NIH SBIR/STTR Diversity Supplement

PA-21-345 Administrative Supplement to Promote Diversity in Research and Development Small Businesses (NIH and CDC)

Purpose: Enhance the diversity of the research and entrepreneurial workforce

- Small Businesses with active small business awards (SBIR/STTR)
- Recruit and support individuals from diverse backgrounds



Career Level

- Undergraduate
- Graduate
- Degree Holders
- Postdoctoral
- Developing Independent Career

https://seed.nih.gov/diversity_supp



Technical and Business Assistance (TABA) Programs

Phase I and Phase II TABA Funding

Grant funds to use your own vendors for Technical and Business Assistance

- \$6,500 per year for a Phase I
- \$50,000 per project for a Phase II Follow Instructions to request funds in the application

Post-Award TABA Programs

Phase I TABA Needs Assessment*

Provides a third-party, unbiased assessment of areas that are critical to success in the competitive healthcare marketplace

Phase II TABA Consulting Services*

Available to *limited number* of awardees in the areas of Intellectual Property, Market Analysis, Regulatory Affairs, or Reimbursement Planning.



TABA Funding Request Best Practices

- Must use a third-party vendor cannot support company personnel
- All instructions in the SF424 (R&R) Application Guide must be followed.
 - Label the requested cost "Technical Assistance" on one of the lines from 8-10.
 - Include a detailed description of the technical or business assistance that your vendor will provide, including the name of the vendor and the expected benefits and results of the technical or business assistance provided in the Budget Justification.
- Budget request needs to be justified
 - Develop a Scope of Work Document* describing your desired deliverables
 - Solicit multiple bids
 - Evaluate all vendor responses before committing
- *SEED's Innovator Support Team can help with SOW development.
 - Reimbursement Sample SOW
 - Intellectual Property Sample SOW
 - Market Analysis Sample SOW



Entrepreneurs in Residence



NIH Entrepreneurs in Residence (EIRs) provide business development guidance and counsel to assist awardees with progress toward commercialization objectives and ensure market success. Each EIR brings unique expertise and experience from their prior and current careers.

- ✓ Fortune 200 companies
- ✓ Corporate/Private Venture Funds
- √ C-suite leadership
- ✓ Entrepreneurs (serial)

Request a Consult

Subject Matter Experts



- NIH Subject Matter Experts (SMEs) provide ad hoc consultations for NIH awardees focused on regulatory and reimbursement topics. Each SME brings unique expertise and experience from their prior and current careers. SMEs have worked in government agencies, healthcare settings, and life science industry.
- ✓ Understanding coding & payment
- ✓ Interactions with FDA
- ✓ Strategy / best practices

Request a Consult

Investor conference opportunities



BIOTECH SHOWCASE™
























100+ companies/year January/June matching

Request Form

Pre-event webinar **Templates Pitch Coaching** Onsite EiR

Most Important Piece of Advice





Talk to a Program Officer at least a month before the application deadline!

Not sure who to contact?

Research Portfolio Online Reporting Tools (RePORT): https://report.nih.gov/

Email: <u>SEEDinfo@nih.gov</u>

List of SBIR Program Managers: https://seed.nih.gov



Hear from your Peers



Phase II Awardees





- Ana Moreno, CEO of Navega Therapeutics
- Navega is developing a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific and long-lasting.
- NINDS: Phase I, Phase II, CRP, Diversity Supplement
- NCI: Phase I, Phase II, Diversity Supplement
- SEED: 3 EiR consults, 2 regulatory consults, BIO attendance support (2x)





- Mo Chen, CEO of Wnt Scientific
- Wnt is developing therapeutic products for musculoskeletal disorders.
- NIAMS: Phase I
- NIA Phase I
- NIDCR: Phase I, Phase II, CRP
- SEED: TABA Needs
 Assessment, TABA Consulting Services, BIO attendance support (1x)



Connect with SEED



Online

http://seed.nih.gov/



Email us

SEEDinfo@nih.gov



@nihseed

https://twitter.com/nihseed



NIH SEED

https://www.linkedin.com/company/nihseed

Sign up for NIH and SEED updates:

https://seed.nih.gov/subscribe

The NIH Guide for Grants and Contracts:

http://grants.nih.gov/grants/guide/listserv.htm

